anti-IL-1beta/anti-IL-18 bispecific monoclonal antibody (Novartis)

N/A

Report date: 2025/03/14 16:48:51

Base Information

Drug Nameanti-IL-1beta/anti-IL-18 bispecific monoclonal antibody (Novartis)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin 18 inhibitorsInterleukin-1 beta inhibitors

TargetsInterleukin-1 betaInterleukin 18

Therapy Area/IndicationsEnterocolitis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharmaceuticals Corp

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharmaceuticals Corp

Inactive CompaniesN/A

Active IndicationsEnterocolitis

Inactive IndicationsN/A

Other Information

ATC CodeN/A